A synergistic cancer immunotherapy nano-system for preventing tumor growth

A synergistic cancer immunotherapy nano-system was developed for treating primary and distant tumors, which may develop a promising strategy to prevent tumor growth for basic and clinical research. [Display omitted] •A synergistic cancer immunotherapy nano-system was synthesized.•MSNs co-loaded with ICG and YM155 for PTT and genotoxic chemotherapy of primary tumors.•MNP coated nSiO2 conjugated with anti-CD47 showed antitumor effect of distant tumors.•The synergistic nano-system could inhibit primary and distant tumor growth in vivo. Immunotherapy has become a promising therapy in cancer treatment. Both photothermal therapy (PTT) and genotoxic chemotherapy can trigger immune responses. On this subject, a synergistic cancer immunotherapy nano-system was developed for treating primary and distant tumors. This long-time, synergistic therapeutic system consisted of two parts: one was indocyanine green (ICG) and sepantronium bromide (YM155) co-loaded mesoporous silica nanoparticles (MSNs) for PTT and genotoxic chemotherapy, which could effectively destroy primary tumors and thus cause exposure of tumor antigens for cancer immunotherapy. The other was silica nanoparticles (nSiO2) coated with magnetic nanoparticles (MNP) and conjugated with anti-CD47 antibody (anti-CD47), which demonstrated a strong antitumor immune effect of distant tumors after PTT and genotoxic chemotherapy. In vitro and vivo results proved that this synergistic system could efficiently inhibit primary and distant tumor growth. We expected that this paper may develop a promising strategy to prevent tumor growth for basic and clinical research.